SPL-006: An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL- 108 Injections When Used in Combination with Paclitaxel in Patients with Platinum resistant, CD44+, Advanced Ovarian Epithelial Cancer
Study of SPL-108 Injections Used in Combination with Paclitaxel in Patients with Advanced Ovarian Epithelial Cancer
Sponsor: Splash Pharmaceuticals, Inc.
Enrolling: Female Patients Only
IRB Number: AAAR9030
U.S. Govt. ID: NCT03078400
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine whether SPL-108 injection might be useful for the treatment of ovarian cancer. The study will evaluate whether SPL-108 can slow the growth and spread of cancerous cells in your body. If you agree, you will be treated with SPL-108 injection in combination with paclitaxel and we will collect blood and tissue samples from you before and during the study for laboratory assessment and radiologic assessment will occur as well
This study is closed
Investigator
June Hou, MD
Do You Qualify?
Have you been diagnosed with recurrent or metastatic epithelial ovarian cancer? Yes No
Have you completed first-line therapy with surgery and chemotherapy? Yes No
Have you had more than 3 prior regimens of chemotherapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Reena Vattakalam
rmv2110@cumc.columbia.edu
212-342-6895
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE